{"id":"054b5e64-f5f1-5e13-92ec-0a99aa0e22df","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-human-inflammasome","predicate":"decreases_in_recorded_comparison","statement":"Apigenin reduced ATP-, MSU- and nigericin-triggered IL-1β release from LPS-primed human monocytes and macrophages.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"3eb87bfe-454d-57ab-9ad5-92ff74e35600","mechanism_event_label":"Apigenin reduced ATP-, MSU- and nigericin-triggered IL-1β release from LPS-primed human monocytes and macrophages.","subject":{"id":"4425961f-4764-56d3-9887-87e47749379b","slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"},"object":{"id":"e9fa1ab4-707e-5ff9-9d60-11f503b54c58","slug":"il1b","display_name":"Interleukin-1 beta / IL1B","entity_type_key":"cytokine"},"evidence_count":1,"mechanism_event":{"id":"3eb87bfe-454d-57ab-9ad5-92ff74e35600","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-human-inflammasome-event","event_type":"experimental_observation","label":"Apigenin reduced ATP-, MSU- and nigericin-triggered IL-1β release from LPS-primed human monocytes and macrophages.","description":"### api-human-inflammasome\n\nApigenin reduced ATP-, MSU- and nigericin-triggered IL-1β release from LPS-primed human monocytes and macrophages.\nFigures 1 and 3. Pharmacological exposure; not demonstrated at oral human parent concentrations.\nModel and exposure: 100 micromolar apigenin after LPS priming; 30-min pretreatment; ATP 3 mM, MSU 200 micrograms/mL or nigericin 10 micromolar.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Apigenin inhibits NLRP3 inflammasome activation in monocytes and macrophages independently of CD38. | 2024 | https://pubmed.ncbi.nlm.nih.gov/39840045/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC11746122/ | https://doi.org/10.3389/fimmu.2024.1497984 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"4425961f-4764-56d3-9887-87e47749379b","slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"},"role":"tested factor","stoichiometry":null,"state_label":"Apigenin before the second activation signal","sequence_order":0,"notes":""},{"entity":{"id":"e9fa1ab4-707e-5ff9-9d60-11f503b54c58","slug":"il1b","display_name":"Interleukin-1 beta / IL1B","entity_type_key":"cytokine"},"role":"measured outcome","stoichiometry":null,"state_label":"decrease","sequence_order":1,"notes":""},{"entity":{"id":"b53e832d-0776-5495-b5cd-cb6a8e8c538b","slug":"nlrp3","display_name":"NLRP3","entity_type_key":"protein"},"role":"activation pathway","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"58b974f1-d389-5bf6-81cd-889c44442c42","slug":"atp","display_name":"ATP","entity_type_key":"small_molecule"},"role":"one activator","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""},{"entity":{"id":"ee396d21-39d5-539e-ba5f-fdc8d8011b16","slug":"monosodium-urate-crystals","display_name":"Monosodium urate crystals","entity_type_key":"small_molecule"},"role":"one activator","stoichiometry":null,"state_label":"","sequence_order":4,"notes":""},{"entity":{"id":"eb449605-97b9-531c-afeb-5c3ac08897a8","slug":"nigericin","display_name":"Nigericin","entity_type_key":"small_molecule"},"role":"one activator","stoichiometry":null,"state_label":"","sequence_order":5,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"Apigenin before the second activation signal\", \"comparator\": \"Same priming and activator without apigenin\", \"endpoint\": \"Apigenin reduced ATP-, MSU- and nigericin-triggered IL-1β release from LPS-primed human monocytes and macrophages.\", \"effect_direction\": \"decrease\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; recorded from source.","entity":null},{"dimension":"experimental_model","value_text":"100 micromolar apigenin after LPS priming; 30-min pretreatment; ATP 3 mM, MSU 200 micrograms/mL or nigericin 10 micromolar.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Recorded from source with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Apigenin collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Apigenin reduced ATP-, MSU- and nigericin-triggered IL-1β release from LPS-primed human monocytes and macrophages.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Apigenin inhibits NLRP3 inflammasome activation in monocytes and macrophages independently of CD38. | https://pubmed.ncbi.nlm.nih.gov/39840045/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC11746122/ | https://doi.org/10.3389/fimmu.2024.1497984","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference api-human-inflammasome; Figures 1 and 3. Pharmacological exposure; not demonstrated at oral human parent concentrations.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"93d1e7c0-d706-5401-8856-f0bec84dfaf5","evidence_kind":"source_excerpt","locator":"Lines 332-338","start_line":332,"end_line":338,"excerpt":"### api-human-inflammasome\n\nApigenin reduced ATP-, MSU- and nigericin-triggered IL-1β release from LPS-primed human monocytes and macrophages.\nFigures 1 and 3. Pharmacological exposure; not demonstrated at oral human parent concentrations.\nModel and exposure: 100 micromolar apigenin after LPS priming; 30-min pretreatment; ATP 3 mM, MSU 200 micrograms/mL or nigericin 10 micromolar.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Apigenin inhibits NLRP3 inflammasome activation in monocytes and macrophages independently of CD38. | 2024 | https://pubmed.ncbi.nlm.nih.gov/39840045/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC11746122/ | https://doi.org/10.3389/fimmu.2024.1497984 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","model_system":"100 micromolar apigenin after LPS priming; 30-min pretreatment; ATP 3 mM, MSU 200 micrograms/mL or nigericin 10 micromolar.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"54eac90b-add1-5f56-9036-d900307c5697","stable_key":"import-ff370329-68a3-573d-96ee-597de78a3967","title":"Apigenin: detailed mechanisms of action (reviewed 10 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed.","file_path":"","sha256":"ede6e5c6b91d66b66844f2ff667a7f8303d9ac1281f15dc09db703f7de4da942","revision_id":"b41a39a2-0197-549c-97a5-1765e6696931","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}